A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.
about
First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II studyPopulation pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxelPemetrexed for the treatment of non-small-cell lung cancer.Refining docetaxel-containing therapy for gastric cancer.Treatment of advanced non small cell lung cancer.Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose.Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer.Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based AnalysisThe role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update.Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelinesThe effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer.Docetaxel-associated epiphora.Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party.Safety and efficacy of single-agent docetaxel (Taxotere) administered weekly in non-small cell lung carcinoma patients in Korea: An observational study.A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinomaWeekly low-dose docetaxel for salvage chemotherapy in pretreated elderly or poor performance status patients with non-small cell lung cancer.Consolidation chwemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis.The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis.Docetaxel monotherapy as second-line treatment for pretreated advanced non-small cell lung cancer patients.New avenues for second-line treatment of metastatic non-small-cell lung cancer.Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer.A study of weekly docetaxel and carboplatin as first-line chemotherapy for advanced non-small cell lung cancer.Refining the treatment of advanced nonsmall cell lung cancer.Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC.Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly?Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.Effect of chemotherapy on quality of life in patients with non-small cell lung cancer.Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.Use of the lung cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development.Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysisEvaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel.Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model.Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer.Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer.
P2860
Q33378383-7E10FA70-41CD-4A28-89DA-3AD5DA196E06Q33795052-6D2D66D2-94A6-44A4-B2C4-FF53D7829ECFQ34464827-0CF4CD06-962D-4523-8EEF-5BFAAE4E3C40Q35003631-31D132ED-6593-4833-8F22-B1779A88FED0Q35445166-3E44917D-23D6-4507-AB03-729A445CDDD2Q35667817-866AE669-BCF6-4A6C-A542-9A428D7CC238Q35674153-7CB852FF-E13E-47E1-B91D-468A68FF0D3BQ35789647-6C2EDB0C-86E4-466A-BB61-83CE77B70A34Q36040002-88C3FF11-125A-4349-9B68-C1CF0626D08DQ36142491-11C029E3-9DE1-4BFB-87DA-2AED354BBAAEQ36412597-2AF5263B-E5DC-4F9C-A831-F4271024CECBQ36448679-8378550F-2AC7-4F0E-801E-4B24BA30F44EQ36484970-76E25BD5-CC72-4585-8582-137B20D2E7C3Q36609433-4BDCBA3F-5F78-4C71-AD10-9080977DE91FQ36636822-A9873D09-F15B-43DD-BC38-AD5EB90EE2A8Q37023744-75B408D1-696A-4A06-8A44-2B3D46E1FFC2Q37030260-13AC10FB-D909-4C70-BE57-93B3787D6BB6Q37108127-EF3080A1-C000-4362-9319-6FD1C8D53F25Q37135295-8E4ADC26-8735-4622-B4EF-35E4B7352DE4Q37205484-A9C0F1CC-926E-44D7-8701-B797A8991555Q37357304-475449F3-EEF5-4215-8CB2-A9A5546502F8Q37598057-A74A8B19-3D09-409E-A53E-B4055499C2EFQ37620539-28E9F6BA-765A-433E-AACC-E9E117017764Q37645169-3E004448-15F4-470A-BFAC-4E2FE3F371FBQ37732287-4ED340CD-4AE7-4E1F-B2E0-C544A3AAD858Q37909780-3EAA4213-EE8A-4DE9-A476-B73AEE7EB991Q37945643-CA7CF55A-635C-43EB-B524-6C4D211C8EDDQ37957744-4D84E466-DB1A-4341-B1FD-90DA315518E1Q38027080-88BD564B-3303-418A-8814-27C36EB609C2Q38190461-067ACBD7-9361-4685-AF2F-91F37E29951DQ38258744-15ECF9D7-EF19-41FA-AFAC-D0A6542D3BD4Q38602994-84432E29-824E-4198-989D-B027BA3E9949Q39139831-B32A59B0-CCE9-48BB-BF9F-EE1E9BEFB308Q40521965-58B9C722-D089-46E6-968E-F4E3E2949689Q41882527-CDF29EBB-2636-4C80-86B2-9F74FADC3FABQ42984481-9A1E942B-E08C-4D67-A39E-FD0D03FADD89Q46448479-4AA2ADE7-D54B-418D-A8AF-526C8CE7A631Q47861831-CC0117BB-5350-46A1-832E-4B38513C6169Q48549299-D5DFEE20-213C-42CF-A59F-89640C8D35E2Q51043526-D1807F04-C1A4-41EA-971E-90030FE98BA2
P2860
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
A randomised clinical trial of ...... g cancer. The DISTAL 01 study.
@ast
A randomised clinical trial of ...... g cancer. The DISTAL 01 study.
@en
type
label
A randomised clinical trial of ...... g cancer. The DISTAL 01 study.
@ast
A randomised clinical trial of ...... g cancer. The DISTAL 01 study.
@en
prefLabel
A randomised clinical trial of ...... g cancer. The DISTAL 01 study.
@ast
A randomised clinical trial of ...... g cancer. The DISTAL 01 study.
@en
P2093
P2860
P50
P356
P1476
A randomised clinical trial of ...... ng cancer. The DISTAL 01 study
@en
P2093
A Ceribelli
C Gridelli
E Barletta
F V Piantedosi
G Palazzolo
L Brancaccio
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602241
P407
P577
2004-12-01T00:00:00Z